Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 2929Neoplasms 2624Lung Neoplasms 1366Colorectal Neoplasms 1328Prostatic Neoplasms 1214Carcinoma, Non-Small-Cell Lung 1079Carcinoma, Hepatocellular 782Stomach Neoplasms 720Pancreatic Neoplasms 701Ovarian Neoplasms 586Colonic Neoplasms 533Uterine Cervical Neoplasms 497Head and Neck Neoplasms 495Rectal Neoplasms 472Melanoma 467Multiple Myeloma 463Esophageal Neoplasms 422Neoplasm Metastasis 418Brain Neoplasms 404Lymphoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 397Urinary Bladder Neoplasms 386Leukemia, Myeloid, Acute 385Leukemia 339Carcinoma, Renal Cell 329Liver Neoplasms 320Endometrial Neoplasms 319Hematologic Neoplasms 312Recurrence 298Disease 272

Interventions

osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × T790M Positive NSCLC Patients × Clear all
NCT03133234 2018-11-20

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

AstraZeneca

Completed
47 enrolled
Thoracic

T790M Positive NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡